An interventional study of Intralesional 5% Dextrose Injection and Perilesional 5% Dextrose Injection in Partial Supraspinatus Tendon Tear, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Shoulder Pain with a site in Turkey — 41 open to participants now, 44 under way, none of them phase 3. Shoulder Pain · Turkey.
Among the 167 studies in Shoulder Pain with a site in Turkey, this one is the 71st largest by enrollment of the 126 interventional ones that give a count, is one of 24 that started in 2025, is one of 124 with no phase, and was the 156th registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →41 of the 167 studies in Shoulder Pain with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–60
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18+
Kübra Sarıoğlu · Sites in Turkey
Ages 20–40 · Healthy volunteers
Istanbul University · Sites in Turkey
Ages 18–65
Ankara City Hospital Bilkent · Sites in Turkey
Ages 40–80
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 60 across 590 interventional studies indexed under Shoulder Pain.
Median enrollment 50 across the 126 interventional studies, 90 across the 41 observational. Of the 116 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 167 has an industry lead sponsor. The 10 most frequent:
Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.
Ankara City Hospital Bilkent has 6 studies filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
13 of the studies in Shoulder Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07513350Istanbul UniversityInvestigation of the Effectiveness of Exercise and Anti-Fibrotic Approaches in Frozen Shoulder | 2026-11 |
| NCT07885215Zonguldak Bulent Ecevit UniversityEffects of Respiratory Muscle Strengthening and Diaphragmatic Breathing on Shoulder Pain and Disability | 2026-12-25 |
| NCT07784543Pamukkale UniversityEffects of Aerobic Exercise on Shoulder Pain, Disability, and Ultrasonographic Outcomes in Patients With Type 2 Diabetes Mellitus With Supraspinatus Tendinopathy | 2027-01-25 |
| NCT07415967Istanbul UniversityThe Effect of a Dual-Task Technique-Based Exercise Program on Clinical Outcomes in Rotator Cuff Related Shoulder Pain | 2027-02-16 |
| NCT07493226Konya Beyhekim Training and Research HospitalEfficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 167 studies in Shoulder Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center randomized trial compared ultrasound-guided intralesional and perilesional 5% dextrose injections in adults with partial supraspinatus tendon tears. Participants and outcome assessors were blinded to group assignment. Forty-six participants were randomized equally to the two groups, and 40 completed follow-up and were included in the final analysis (20 per group).
Both groups received ultrasound-guided injections at baseline and at study weeks 3 and 6. At each session, both groups received a 5% dextrose injection at the supraspinatus tendon attachment. An additional injection was given either directly into the tear or into the tendon tissue around it, depending on group assignment. Both groups began the same home exercise program after the first injection.
Shoulder pain, disability, and health-related quality of life were assessed at baseline and at study weeks 9 and 12. Tear dimensions and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
This prospective, single-center, parallel-group randomized trial enrolled adults aged 18 to 75 years with symptomatic partial supraspinatus tendon tears. An independent researcher generated the 1:1 allocation sequence using a computer-based random number generator. Allocation was concealed in sequentially numbered, opaque, sealed envelopes. The injecting physician opened the envelopes after the baseline clinical and ultrasonographic assessments. Participants and outcome assessors were blinded to group assignment.
Both groups received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, 2 mL was distributed across three points at the supraspinatus tendon enthesis in both groups. An additional 2 mL was injected into the tendon defect in the intralesional group or into the tendon tissue surrounding the defect in the perilesional group using a peppering technique. The total injection volume was 4 mL per session in both groups. Participants began the same standardized home exercise program after the first injection and were instructed to perform it twice daily throughout the study.
Clinical outcomes were assessed at baseline and at study weeks 9 and 12. Mean daytime pain, worst daytime pain, and night pain were recorded separately using the Numeric Rating Scale. Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index, and health-related quality of life was assessed using the 12-Item Short Form Health Survey. Short-axis and long-axis defect diameters and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants with bilateral involvement, only the more painful shoulder was included.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and directly into the partial tendon tear. Participants began the same standardized home exercise program as the perilesional group after the first injection.
Procedure: Intralesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and into the tendon tissue surrounding the margins of the partial tear. Participants began the same standardized home exercise program as the intralesional group after the first injection.
Procedure: Perilesional 5% Dextrose Injection
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected directly into the partial tendon defect using a peppering technique. The total volume was 4 mL per session.
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected into the tendon tissue surrounding the margins of the partial tear using a peppering technique. The total volume was 4 mL per session.
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale
Mean daytime shoulder pain, worst daytime shoulder pain, and night pain were assessed separately using an 11-point Numeric Rating Scale (NRS). Each score ranged from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity.
Time frame: Baseline and study weeks 9 and 12.
Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index
The Shoulder Pain and Disability Index (SPADI) was used to assess shoulder pain and disability. The pain subscale contains 5 items, and the disability subscale contains 8 items. The two subscales were scored separately on a 0-100 scale. Higher scores indicated greater pain or disability.
Time frame: Baseline and study weeks 9 and 12.
Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey
Health-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated separately. Higher scores indicated better health-related quality of life in the corresponding component.
Time frame: Baseline and study weeks 9 and 12.
Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography
Supraspinatus tendon thickness was measured in millimeters using shoulder ultrasonography with a 5-12 MHz linear transducer.
Time frame: Baseline and study week 12.
Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography
The short-axis and long-axis diameters of the partial supraspinatus tendon tear were measured separately in millimeters using electronic calipers on the ultrasound images that best displayed the defect.
Time frame: Baseline and study week 12.
Plan to share: No — Individual participant data will not be shared due to privacy and ethical restrictions.
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Feb 2026, 12 months.
Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 12 months is close to that.
Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Feb 2026 and completion Oct 2026 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara City Hospital Bilkent →